Prince Alfred Singh։ Understanding Antithrombin III Deficiency as a High-Risk Thrombophilia
Prince Alfred Singh, Medical Officer at Addu Equatorial Hospital (AEH), shared a post on LinkedIn:
“Understanding Antithrombin III Deficiency: A High-Risk Thrombophilia
Antithrombin III (AT III) plays a critical role as the body’s natural anticoagulant – primarily inhibiting thrombin (IIa) and factor Xa to prevent excessive clot formation.
What happens in AT III deficiency?
A reduction in this key inhibitor shifts the hemostatic balance toward thrombosis, making it one of the most clinically significant inherited thrombophilias.
Key Facts:
- Inherited in an autosomal dominant pattern
- Prevalence: approximately 1 in 3,000 individuals
- Strongly associated with recurrent venous thromboembolism (VTE)
- Arterial events are less common but can occur
Risk Perspective:
Compared to other thrombophilias such as Factor V Leiden or Protein C deficiency, AT III deficiency carries one of the highest relative risks for VTE.
Clinical Management Insights:
- Many patients require long-term anticoagulation (e.g., warfarin)
- Heparin resistance can occur due to low AT levels
- In pregnancy: heparin-based therapy is preferred
- Consider AT concentrate in selected high-risk scenarios
Clinical Takeaway:
- Early recognition is essential—especially in patients with:
- Recurrent unexplained VTE
- Strong family history of thrombosis
- Thrombosis at a young age
A tailored, lifelong management strategy can significantly reduce morbidity and prevent life-threatening complications.”
Stay updated with Hemostasis Today.
-
May 31, 2026, 16:29José Antonio García Erce: Collaborative PBM Implementation in Transfusion Centers and Services
-
May 31, 2026, 16:22Vera Ignjatović: How Do We Rigorously Study These Drugs in Children to Understand Their True Benefits and Risks?
-
May 31, 2026, 16:21Ksenija Stach: Is This The Future of Lipid-Lowering Lherapy?
-
May 31, 2026, 15:42Antonio Greco: Balancing Bleeding and Thrombotic Risk After PCI
-
May 31, 2026, 15:41Eric Topol: Replication of Plasma p-tau217 Blood Test for Predicting Alzheimer’s Disease
-
May 31, 2026, 15:32ASH Invites Dynamic Members to Apply for 2027 Leadership and Committee Roles
-
May 31, 2026, 14:39Monique Gore-Massy: Redefining Lupus Innovation Through Patient Partnership
-
May 31, 2026, 14:31Mirjam Teboe: The Golden Rule Behind Reliable Lupus Anticoagulant Testing
-
May 31, 2026, 14:20Improving Access to Care for People Living with Haemophilia and Haemoglobinopathies – NNHF